List/Grid Tag Archives: therapies

CNCF 2010 ~ Allogeneic (donor) stem cell transplant for neuroblastoma

New donor transplant trial open for relapsed or refractory neuroblastoma Dr Sandeep Soni spoke at CNCF (Children’s Neuroblastoma Cancer Foundation) Parent Conference in Chicago July 10, 2010. Dr Soni is a member of the Pediatric Blood and Marrow Transplant program at Nationwide Children’s Hospital and an Assistant Professor of Clinical Pediatrics at Ohio State University College of Medicine ...

New vaccine trial for relapsed/refractory neuroblastoma in combination with metronomic chemotherapy

Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC) Researchers at Texas Children’s Hospital/Center for Cell and Gene Therapy, Baylor College of Medicine will begin accruing patients soon on a new phase I/II trial using an allogeneic neuroblastoma vaccine with low-dose chemotherapy. Drs Chrystal Louis and Malcom Brenner are the principal ...

New frontline high-risk neuroblastoma trial includes MIBG transplant

Pilot study: 131I-MIBG radiotherapy with chemotherapy after induction for newly diagnosed Dr Greg Yanik (University of Michigan) presented preliminary results of the NANT (New Approaches to Neuroblastoma Therapy) NANT-2001-02 phase 2 MIBG + CEM (131I-MIBG radiotherapy with carboplatin, etoposide, and melphalan) stem cell transplant trial on June 23rd 2010 at the Advances in Neuroblastoma Research ...

New oncolytic virus clinical trials listed

Three new oncolytic virus trials to treat neuroblastoma: vaccinia (JX-594), herpes simplex (HSV1716), and Newcastle Disease virus Vaccinia JX-594 A Phase I, Open-Label, Dose Escalation Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by Intratumoral Injection in Pediatric Patients With Unresectable Refractory Solid Tumors A phase I study using intratumoral injection ...

CNCF 2010 ~ Seneca Valley Virus NTX-010 is first oncolyic virus ever used in US children

Dr Michael Burke from the University of Minnesota is the Principal Investigator of the Seneca Valley Virus trial COG-ADVL0911: “Seneca Valley Virus-001 in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features” Dr Burke gave a presentation on this trial at the CNCF parent conference July 10, 2010. By early July, ...

Perifosine awarded orphan drug status, again

http://online.wsj.com/article/BT-CO-20100714-708425.html DOW JONES NEWSWIRES Keryx Biopharmaceuticals Inc. (KERX) said the U.S. Food and Drug Administration has given orphan-drug designation to perifosine, a treatment for cancer including neuroblastoma, or cancer of the nervous system in infants. Shares of the biopharmaceutical company jumped 13% to $4.04 in recent trading, while U.S.-traded shares ...

ASCO 2010 ~ Abstract impact and drugs for neuroblastoma

Significance of abstracts submitted to ASCO The meeting at ASCO (America Society of Clinical Oncology) provides a prime opportunity for oncologists and other researchers to present results of clinical trials and studies before publication in peer-reviewed journals. This year ASCO had over 5000 abstracts submitted. Abstracts are reviewed for scientific and practice-changing merit and some are selected ...
© 2014 NB Globe ~ Neuroblastoma News. All rights reserved. | Contact Us